Yayoi Kajiwara

Learn More
The prospective feasibility study was designed to determine whether treatment with antithrombin (AT) concentrates could be used for patients with severe preeclampsia to provide clinical efficacy without the full systemic antihypertensive drug. Twenty-nine severe preeclamptic patients (24 to 36 weeks of gestation, gestosis index [GI] >/= 6 points) were(More)
A 55-year-old woman with a giant cavernous hemangioma in the liver with hemoperitoneum due to blunt abdominal trauma was reported. CT findings of the liver at first thought to be hepatic injuries. But serial studies revealed that the CT findings were dependent on giant cavernous hemangioma and apart from hepatic injury.
AIM To see if antithrombin (AT) supplementation improved fetal outcomes in early onset (<32 weeks) severe pre-eclampsia. METHODS A subgroup re-analysis of an original randomized controlled trial of AT in pre-eclampsia between 24 and 35 weeks of gestation was performed. Either AT (3000 IU/day, n=42) or placebo (Albumin 582 mg/day, n=42) were administered(More)
  • 1